Evaluations of a Commercial CLEANBOLUS-WHITE for Clinical Application
10.14316/pmp.2024.35.1.10
- Author:
Geum Bong YU
1
;
Jung-in KIM
;
Jaeman SON
Author Information
1. Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea
- Publication Type:Original Article
- From:
Progress in Medical Physics
2024;35(1):10-15
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:This study aimed to comprehensively investigate the diverse characteristics of a novel commercial bolus, CLEANBOLUS-WHITE (CBW), to ascertain its suitability for clinical application.
Methods:The evaluation of CBW encompassed both physical and biological assessments. Physical parameters such as mass density and shore hardness were measured alongside analyses of element composition. Biological evaluations included assessments for skin irritation and cytotoxicity. Dosimetric properties were examined by calculating surface dose and beam quality using a treatment planning system (TPS). Additionally, doses were measured at maximum and reference depths, and the results were compared with those obtained using a solid water phantom. The effect of air gap on dose measurement was also investigated by comparing measured doses on the RANDO phantom, under the bolus, with doses calculated from the TPS.
Results:Biological evaluation confirmed that CBW is non-cytotoxic, nonirritant, and nonsensitizing. The bolus exhibited a mass density of 1.02 g/cm 3 and 14 shore 00. Dosimetric evaluations revealed that using the 0.5 cm CBW resulted in less than a 1% difference compared to using the solid water phantom. Furthermore, beam quality calculations in the TPS indicated increased surface dose with the bolus. The air gap effect on dose measurement was deemed negligible, with a difference of approximately 1% between calculated and measured doses, aligning with measurement uncertainty.
Conclusions:CBW demonstrates outstanding properties for clinical utilization. The dosimetric evaluation underscores a strong agreement between calculated and measured doses, validating its reliability in both planning and clinical settings.
